Dacomitinib is a Small Molecule owned by Pfizer, and is involved in 50 clinical trials, of which 39 were completed, 10 are ongoing, and 1 is planned.

Dacomitinib (PF-00299804) is highly selective, second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential anti-neoplastic activity. EGFR inhibitor PF-00299804 specifically and irreversibly binds to and inhibits human EGFR subtypes (HER-1, HER-2 and HER-4) resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells. EGFRs play major roles in tumor cell proliferation and tumor vascularization, and are often over-expressed or mutated in various tumor cell types.

The revenue for Dacomitinib is expected to reach a total of $1.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dacomitinib NPV Report.

Dacomitinib is originated and owned by Pfizer.

Dacomitinib Overview

Dacomitinib (Vizimpro) is a quinazolinamines derivative, acts as an anti-neoplastic agent. It is formulated as film coated tablets for oral route of administration. Vizimpro is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon-19 deletion or exon-21 L858R substitution mutations, also as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.

Dacomitinib (PF-00299804) is under development for the treatment of non-small cell lung cancer as a first line therapy. It is administered orally. The drug candidate is a new molecular entity (NME). It was also under development for solid tumors including resectable oral cavity cancer, relapsed/recurrent glioblastoma, skin squamous cell cancer, and squamous cell carcinoma of the penis, gastric cancer and recurrent or metastatic squamous cell carcinoma of the head and neck, metastatic or recurrent esophageal squamous cell carcinoma, colorectal cancer, pancreatic cancer, leptomeningeal disease and adenocarcinoma of the stomach or gastro-oesophageal junction.

Pfizer Overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.

Quick View – Dacomitinib

Report Segments
  • Innovator (NME)
Drug Name
  • Dacomitinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.